Haematopoietic stem cell transplantation with non‐myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution
- 23 March 2004
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 125 (2) , 225-231
- https://doi.org/10.1111/j.1365-2141.2004.04897.x
Abstract
Thirty patients with haematological malignancies received peripheral blood stem cells from human leucocyte antigen (HLA)-identical sibling donors after non-myeloablative conditioning with fludarabine and total body irradiation. Twenty-seven patients received the transplant as an outpatient procedure. All patients engrafted. The probability of acute graft-versus-host disease (GVHD) grades II-IV and extensive chronic GVHD was 57% and 80%, respectively. Patients alive on day +365 experienced a median of 44 d (range 4-151) of hospitalization during the first year. In the entire cohort, GVHD accounted for 22%, infections for 18%, thrombotic thrombocytopenic purpura (TTP) for 16% and engraftment syndrome for 14% of the time in hospital. The 1-year risk of TTP was 26%. Acute GVHD was a risk factor for the development of TTP (P = 0.008). With a median follow-up of 602 d, the 2-year estimates for overall survival, progression-free survival, non-relapse mortality and relapse related mortality were 68%, 43%, 22% and 13%, respectively. This transplantation regimen is feasible and induces long-term remissions in heavily pretreated patients. The procedure can be performed in the outpatient setting, but complications could result in a substantial number of admissions during the first year.Keywords
This publication has 22 references indexed in Scilit:
- Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myelomaBlood, 2003
- Low-dose total-body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA-identical sibling donors do not induce complete T-cell donor engraftment in most patients with progressive hematologic diseasesExperimental Hematology, 2003
- Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioningBlood, 2003
- Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantationBlood, 2003
- Posttransplantation Thrombotic Thrombocytopenic Purpura: A Single-Center Experience and a Contemporary ReviewMayo Clinic Proceedings, 2003
- Non‐myeloablative allografting from human leucocyte antigen‐identical sibling donors for treatment of acute myeloid leukaemia in first complete remissionBritish Journal of Haematology, 2003
- Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT)British Journal of Haematology, 2002
- Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomesBone Marrow Transplantation, 2001
- Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationBlood, 2001
- Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignanciesTransplantation and Cellular Therapy, 2000